The Role of FDG- PET/CT in Detecting Bone Marrow Involvement in Childhood Solid Tumors
Nuklearmedizin - NuclearMedicine · 01.06.2024 · 63 (03) · 207-212
DOI: 10.1055/a-2224-9441 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.06.2024. Verfasst von Esra Arslantaş und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology Oncology, Başakşehir Çam ve Sakura Şehir Hastanesi, Istanbul, Turkey. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Sensitivity and Specificity, Radiopharmaceuticals. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Purpose
To compare the results of 18F-Fluorodeoxy positron emission tomography/computed tomography (18 F-FDG-PET/CT) and bone marrow biopsy (BMB) procedures in the initial evaluation of bone marrow involvement (BMI) in pediatric solid tumors.
Methods
We conducted a retrospective analysis of newly diagnosed pediatric cases with lymphoma, neuroblastoma, Ewing sarcoma, rhabdomyosarcoma. Each case underwent both PET-CT imaging and BMB. Presence of tumor infiltration in BMB specimens and/or positive FDG-PET/CT findings indicate as BMI were regarded as true positive results.
Results
Sixty-four patients were included in the study. BMI was detected in 23/64 (36%) patients, FDG-PET/CT imaging and BMB results were concordant in 54/64 patients. In 9/64 patients the finding was FDG-PET/CT (+), BMB (-) indicating a false negative BMB result. In only 1/64 patients FDG- PET/CT (-), BMB (+), indicating a false negative FDG-PET/CT result. In the whole patient group, the sensitivity, specificity, positive predictive value and negative predictive value of PET/CT and BMB in detecting bone marrow involvement were 95.6%, 100%, 100% and 97.6% and 60.8 %, 100%, 100% and 82%, respectively.
Conclusion
PET/CT has a high sensitivity and specificity for the assessing marrow involvement in pediatric solid tumors. We believe that PET/CT imaging should be performed as the first step in diagnostic staging, and BMB may not be necessary in every patient, only in patients with suspicious PET/CT results for bone marrow involvement. Additionally, for a more precise determination of bone marrow involvement, it is reasonable to perform BMB from FDG-retaining areas, using PET/CT as a guide tool.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pediatric Hematology Oncology, Başakşehir Çam ve Sakura Şehir Hastanesi, Istanbul, Turkey.
- Department of Nuclear Medicine, Başakşehir Çam ve Sakura Şehir Hastanesi, Istanbul, Turkey.
Zitieren
APA
Arslantaş, E., Ayçiçek, A., Esen Akkas, B., Tahtakesen Güçer, T. N., Okur Acar, S., Özkan Karagenc, A., Akpınar Tekgündüz, S., & Bayram, C. (2024). The Role of FDG- PET/CT in Detecting Bone Marrow Involvement in Childhood Solid Tumors. Nuklearmedizin - NuclearMedicine, 63(03), 207-212. https://doi.org/10.1055/a-2224-9441
Vancouver
Arslantaş E, Ayçiçek A, Esen Akkas B, Tahtakesen Güçer TN, Okur Acar S, Özkan Karagenc A, et al. The Role of FDG- PET/CT in Detecting Bone Marrow Involvement in Childhood Solid Tumors. Nuklearmedizin - NuclearMedicine. 2024;63(03):207-212. doi:10.1055/a-2224-9441
BibTeX
@article{Arslanta2024,
author = {Arslantaş, Esra and Ayçiçek, Ali and Esen Akkas, Burcu and Tahtakesen Güçer, Tuba Nur and Okur Acar, Sultan and Özkan Karagenc, Ayse and Akpınar Tekgündüz, Sibel and Bayram, Cengiz},
title = {The Role of FDG- PET/CT in Detecting Bone Marrow Involvement in Childhood Solid Tumors},
journal = {Nuklearmedizin - NuclearMedicine},
year = {2024},
volume = {63},
number = {03},
pages = {207--212},
doi = {10.1055/a-2224-9441}
}
EUVIMED